Open company graph database — free web & API
Login

Tetra Therapeutics

テトラセラピューティクスAlias
Ticker
—
Listed market
—
Country
United States of America
Employees (non-consolidated)
—
Related companies
1
§01

Basic information

BASIC
Head office
United States, Michigan
Chief executive
Employees (non-consolidated)
Employees (consolidated)
Start date
End date
§02

Websites

1 DOMAINS
§03

Business

4
Drug development for neurodegenerative diseasesProtein structure-based drug designDiscovery of negative allosteric modulators for phosphodiesterase 4Research and development of therapeutics for fragile X syndrome, Alzheimer's disease, traumatic brai
§04

Related companies

1 COMPANIES
Company name Group Parent Subsidiary Customer Supplier Alliance Bank Shareholder
Shionogi Inc.
Group
Names without a link are companies not yet registered in OpenBizGraph
§05

Network

NETWORK
Drag to move · click to open
§06

History

16 EVENTS

On March 17, 1878, on his 24th birthday, he became independent and founded the drugstore "Shiono Gisaburo Shoten" at 3-12 Dojima-machi, Osaka.Sources

Eight years after founding, in 1886, Western medicine began to spread widely, and imported Western medicines started to be sold.Sources

In 1909, Gizo's second son, Chojiro, graduated from the Department of Pharmacology at the University of Tokyo, and SHIONOGI began full-scale pharmaceutical research. Chojiro started trial manufacturing, and the stomach acid suppressant "Antaciden," which was successfully commercialized, became the first new drug developed in-house by Shiono Gisaburo Shoten.Sources

In 1909, the balance mark was registered as a trademark. The symbol of SHIONOGI is derived from the "balance" used to measure medicine, symbolizing accuracy, honesty, and trust.Sources

In 1910, a pharmaceutical factory, "Shiono Pharmaceutical Factory," was newly built in Nishinari District, Osaka Prefecture, and started full-scale operation in 1910.Sources

In 1943, the company name was changed to Shiono Giyaku Co., Ltd.Sources

In 1945, due to rapid inflation and soaring prices after the end of the war, SHIONOGI was almost bankrupt and fell into the worst management condition since its founding.Sources

In 1950, the painkiller "Cedes" was launched.Sources

In 2011, acquired Chinese pharmaceutical company C&O Pharmaceutical Technology (Holdings) Limited.Sources

In 2012, established Shionogi Limited, a development subsidiary, in the UK.Sources

In 2014, with the vision of growing as a drug discovery-oriented pharmaceutical company, set ROE as one of the management indicators, clarified the items to be achieved over the past three years, and clearly indicated efforts toward the management goal of 2020 while reviewing results and issues annually in a rolling manner.Sources

Establishment of a joint venture company with Shimadzu Corporation, "AdvanSentinel Inc."Sources

Establishment of the general incorporated foundation, "Shionogi Infectious Disease Research Promotion Foundation"Sources

Development of the SHIONOGI group brand and the establishment of the group brand markSources

Establishment of Yui Connection Inc.Sources

Launch of the COVID-19 treatment drug "Zocova"Sources

§07

News

0 ARTICLES

There is no news.

§09

Sources & updates

SOURCES
↑